论文部分内容阅读
目的探讨TACE治疗肝癌的不良反应情况,为其临床防治提供依据。方法通过回顾性分析81例(Child-pugh A级)肝癌切除术后复发患者TACE术后出现的不良反应情况,与同期同级的267例初诊中晚期肝癌患者进行对比。结果复发组ALT、AST在TACE术后1周恢复至术前水平,而STB、DBIL、STP、A、ChE在术后2周恢复至术前水平,无严重不良反应;中晚期组肝功能均需要2周才能恢复至术前水平。结论 Child-pugh A级肝癌在TACE术后肝功能损害为可逆性;TACE对肝脏合成功能及储备功能损伤持续时间长,恢复较慢。
Objective To investigate the adverse reactions of TACE in the treatment of liver cancer and provide the basis for its clinical prevention and treatment. Methods A retrospective analysis of 81 cases (Child-pugh A grade) recurrence after resection of liver cancer patients TACE postoperative adverse reactions, with the same period 267 cases of newly diagnosed patients with advanced liver cancer were compared. Results The levels of ALT and AST in the recurrence group returned to the preoperative level at 1 week after TACE, while the levels of STB, DBIL, STP, A and ChE returned to the preoperative level at 2 weeks after operation, and no serious adverse reactions were found. It takes 2 weeks to return to preoperative level. Conclusions Child-pugh grade A hepatocellular carcinoma has reversible liver damage after TACE. TACE has a long duration of recovery and slow recovery of liver function and reserve.